Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Off Therapy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Stimulant Medication Effects on Auditory Sensitivity in Teens With ADHD

NCT04577417
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder, Attention Deficit Disorder With Hyperactivity
Interventions
ADHD stimulants, for example, amphetamine, dexmethylphenidate, dextroamphetamine, methylphenidate
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 4, 2026, 7:48 PM EDT
Recruiting Phase 4 Interventional

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

NCT05593055
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy
Interventions
Eplerenone, Chlorthalidone, Potassium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Fulvestrant, Anastrazole
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 4, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

NCT06409390
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Taxotere, Cytoxan, Trastuzumab deruxtecan, Sacituzumab govitecan, Xeloda, Fulvestrant, Ribociclib, Abemaciclib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

NCT01149083
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Veliparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 4, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

NCT07659795
View directory record Official record
Conditions
Colorectal Cancer
Interventions
VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Los Angeles, California • Tampa, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Bacterial Decolonization Within Dyads

NCT06541145
View directory record Official record
Conditions
Bacterial Colonization
Interventions
Mupirocin, Chlorhexidine baths
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

A Study to Investigate the Safety and Clinical Effect of Nexagon® as a Topical Treatment for Subjects With a Diabetic Foot Ulcer (DUNE)

NCT01490879
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Nexagon® Low Dose, Nexagon® Medium Dose, Nexagon® High Dose, Nexagon® vehicle
Drug
Lead sponsor
OcuNexus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 3 Interventional Results available

Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma

NCT00720941
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pazopanib, Sunitinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
96
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 4, 2026, 7:48 PM EDT
Terminated Phase 2 Interventional

Optimization for Regorafenib in HCC

NCT04476329
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Regorafenib 40 MG
Drug
Lead sponsor
SC Liver Research Consortium, LLC
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
9
States / cities
Gilbert, Arizona • Long Beach, California • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Not applicable Interventional Results available

Dexcom Continuous Glucose Monitoring in Long-term Care

NCT04818242
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Dexcom G6 CGM with GTS, POC Blood Glucose Test + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 4, 2026, 7:48 PM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

NCT04267120
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Research blood collection
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Palo Alto, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

NCT02187783
View directory record Official record
Conditions
Tumors With CDK4/6 Pathway Activation
Interventions
LEE011
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
61
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 4, 2026, 7:48 PM EDT
Not listed No phase listed Observational

The Diabetic Foot Ulcer Registry

NCT02813161
View directory record Official record
Conditions
Diabetic Foot Ulcer Outcome, Quality of Patient Care
Interventions
cellular and tissue based therapy, negative pressure wound therapy, debridement, advanced wound therapy, Nutritional screening, off-loading, Hyperbaric oxygen Therapy
Biological · Device · Procedure + 1 more
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Sep 4, 2026, 7:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Dysfunction in Women With Newly Diagnosed Breast Cancer Compared to Healthy Volunteers

NCT00336102
View directory record Official record
Conditions
Breast Cancer, Fatigue, Hypothyroidism
Interventions
physiologic testing, fatigue assessment and management, management of therapy complications
Other · Procedure
Lead sponsor
University of South Florida
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
41
States / cities
Phoenix, Arizona • Greeley, Colorado • Loveland, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

NCT00813865
View directory record Official record
Conditions
Gaucher Disease, Type 1 Gaucher Disease, Gaucher Disease, Type 1
Interventions
afegostat tartrate
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Coral Springs, Florida • Decatur, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

NCT03315039
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Liposomal Annamycin
Drug
Lead sponsor
Moleculin Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
La Jolla, California • Gainesville, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 1 Interventional

A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS

NCT04582201
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
agenT-797
Drug
Lead sponsor
MiNK Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Santa Monica, California • Louisville, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 4, 2026, 7:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures

NCT06227039
View directory record Official record
Conditions
Pain, Acute, Vocal Fold Polyp, Vocal Cord Paralysis, Laryngeal Neoplasms
Interventions
Vibroacoustic stimulation on, Augmented Reality on, Vibroacoustic stimulation off, Augmented reality off
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 4, 2026, 7:48 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP

NCT01939067
View directory record Official record
Conditions
Respiratory Distress, Lung Injury
Interventions
Heated Humidified High Flow Nasal Cannula, Nasal Continuous Positive Airway Pressure
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Hours to 72 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2015 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

NCT01913639
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Regorafenib, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 4, 2026, 7:48 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Keeping Weight Off: Brain Changes Associated With Healthy Behaviors

NCT02189187
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Mindfulness, Psychoeducation
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
25 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 4, 2026, 7:48 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

NCT01940471
View directory record Official record
Conditions
HBeAg-positive Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
875 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 4, 2026, 7:48 PM EDT